ClinicalTrials.gg
RecruitingNCT07280754Updated Nov 3, 2026

Evaluation of 25(OH)D3 and LL-37 Levels in Periimplant Sulcus Fluid

An observational study in Peri Implantitis and Peri Implant Mucositis, sponsored by Recep Tayyip Erdogan University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Recep Tayyip Erdogan University · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Updated Nov 3, 2026Now RecruitingFirst site in Turkey (Türkiye)+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
72
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Peri-Implantitis with a site in Turkey — 16 open to participants now, 19 under way, none of them phase 3. Peri-Implantitis · Turkey.

Planned enrollment
17th of 29
72 · median 87
Started
2025
with 7 others
Observational
29 of 55
6 open now
Primary completion
2027-06
later than 16 of 18 live
Registered
37th of 55
by date
Lead sponsor
2 of 55
Recep Tayyip Erdogan University

Among the 55 studies in Peri-Implantitis with a site in Turkey, this one is the 17th largest by planned enrollment of the 29 observational ones that give a count, is one of 8 that started in 2025, is one of 29 observational ones, reaches primary completion later than 16 of the 18 other live ones, and was the 37th registered.

Peri-Implantitis

324 studies on the registry are indexed under Peri-Implantitis; 89 are open to participants now.

Browse Peri-Implantitis studies →

Open to participants now

16 of the 55 studies in Peri-Implantitis with a site in Turkey are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 50 Peri-Implantitis studies recruiting now, 28 (56%) set no upper age limit and 9 (18%) stop at 75 or younger; 7 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Peri-Implantitis with a site in Turkey, or all of them as a file.
02

Study summary

Despite technological advances that have significantly improved dental implant osseointegration and survival rates, biological complications such as peri-implantitis and peri-implant mucositis are common around the implant. The active form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), can be induced by the expression of leucine-lysine-37 (LL-37), a human antimicrobial peptide in the cathelicidin family. Studies have shown that 1,25(OH)2D3 and its precursor, 25(OH)D3, significantly reduce inflammation by suppressing the release of receptor activator nuclear factor kappa b ligand (RANKL), tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1, and IL-6, and by preventing alveolar bone loss. To date, many cytokines have been investigated in peri-implant sulcus fluid (PIOS). The lack of a direct study investigating vitamin D and LL-37 levels in PIOS constitutes the unique value of this project. This study aims to compare LL-37 and 25(OH)D3 levels in PIOS and examine their correlation with markers such as IL-6, IL-10, and MMP-8, as well as clinical parameters. Volunteers aged 18-65 who have received dental implants at the Recep Tayyip Erdoğan University Faculty of Dentistry and have been using their implant-supported prosthesis for at least one year and who have been informed about this study will be included in the study. The groups will be formed as peri-implant health, peri-implant mucositis, and peri-implantitis. The implants of the patients included in the study will be evaluated for probed pocket depth (PPD), clinical attachment level (CAL), suppuration (S), modified gingival index (mGI), plaque index (mPI), bleeding index (mBI), keratinized gingival amount, and attached gingival amount. PIOS and serum samples will be obtained from patients, and their relationship to periodontal status and each other will be statistically evaluated.

This project may help discover new biomarkers that can be used in the early diagnosis of peri-implantar diseases. This study could contribute to earlier treatment, lower patient costs, and even the development of new treatment plans for these diseases.

03

Conditions studied

  • Peri Implantitis
  • Peri Implant Mucositis

Browse trials for

Keywords

  • LL-37
  • peri-implanter sulcus fluid
  • peri-implantitis
  • vitamin D
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The G*Power analysis performed to determine the number of samples to be included in the study determined that a total of 72 samples/implants should be included, with a minimum of 24 in each group, when the power of the test was taken as 0.85, the effect size as 0.4, and the Type-1 error (α) as 0.05.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being between the ages of 18-65,
  • Having dental implants and using implant-supported prostheses for at least one year,
  • Not having used systemic and/or topical antibiotics/anti-inflammatory drugs or mouthwashes in the last three months,
  • Not having received periodontal/peri-implant treatment in the last six months.

Exclusion criteria

Exclusion Criteria:

  • Having a systemic disease or condition that affects peri-implant status,
  • Having a metabolic bone disease,
  • Bruxism,
  • Being pregnant or lactating,
  • Having received periodontal/peri-implant treatment within the last 6 months,
  • Smoking and alcohol use,
  • Taking vitamin D supplements.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
72 participants (estimated)
Patient registry
No

Groups and cohorts

  • healthy group

    Criteria such as absence of clinical signs of inflammation in the tissues, absence of bleeding on probing, PPD ≤5.0 mm, and absence of bone loss greater than 2 mm after initial healing will be sought.

  • peri-implant mucositis

    Criteria such as clinical signs of inflammation (erythema, swelling, suppuration) in the tissues, bleeding on probing, and an PPD of 5.0 mm will be sought. At the time of implant placement, the height of the surrounding soft tissue influences the initial probing depth.

  • periimplantitis

    Bleeding, inflammation, redness, edema, suppuration, and in addition to these, bone loss \>5 mm and radiographically observed in PPD are observed in the tissues.

06

What researchers measure

Primary outcomes

  1. Probing pocket depth (PPD)

    The distance from the gingival margin to the pocket base around the implants was measured in mm using a periodontal probe, at six locations for each implant. The average value will be determined for each implant circumference.

    Time frame: baseline

  2. clinical attachment level (CAL)

    Similar to the PPD measurement, this will be done by determining the distance between the pocket base and the implant neck.

    Time frame: baseline

Secondary outcomes

  1. 25-Hydroxy Vitamin D3 ((25(OH)D3))

    25(OH)D3 levels in PIOS samples will be analyzed by ELISA or CMIA methods.

    Time frame: baseline

  2. leucine leucine-37 (LL-37)

    LL-37 levels in PIOS samples will be evaluated by ELISA method.

    Time frame: baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jun 2027, 17 months after the start.

Of 33 non-industry observational studies under Peri-Implantitis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 77. This study's planned 17 months is close to that.

Counting every sponsor, half of 35 studies reached it within 17 months; a quarter within 8 and three quarters within 77.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Apr 2026 → Jun 2027 and completion Jun 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Dec 12, 2025
StartActual
Dec 30, 2025
Primary completionEst.
Jun 1, 2027was Apr 2026
CompletionEst.
Jun 1, 2027was Jun 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 3, 2026
Sites
1 site added — first site in Turkey (Türkiye)
Show site
  • Recep Tayyip Erdoğan University · Rize, Turkey (Türkiye)
Nov 3, 2026
Primary completion
Apr 1, 2026→Jun 1, 2027
Nov 3, 2026
Study completion
Jun 1, 2026→Jun 1, 2027
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Turkey (Türkiye)
    Show site
    • Recep Tayyip Erdoğan University · Rize, Turkey (Türkiye)
    Primary completion Apr 1, 2026→Jun 1, 2027
    Study completion Jun 1, 2026→Jun 1, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07280754
Lead sponsor
Recep Tayyip Erdogan University
Responsible party
Melek Beder (Doctor, Recep Tayyip Erdogan University) — Principal investigator
First posted
Dec 12, 2025
Start date
Dec 30, 2025
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Nov 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion